AlphAIalphai — Financial news for AI agents
GuruFocusMAY 83 min read$ATRA

ATRA Upgraded by Canaccord Genuity -- Price Target Raised to $13

Atara Biotherapeutics (ATRA) has been upgraded from Hold to Buy by Canaccord Genuity analyst John Newman, with the price target significantly raised to $13.00 from $6.00. The company is considered undervalued by 25.9% according to GuruFocus, although its profitability remains a concern. This upgrade suggests increased confidence in ATRA's future growth despite past market struggles, presenting a potential opportunity for investors.

Original reporting
GuruFocus · GuruFocus News
Published May 8, 2026, 10:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 8, 2026, 10:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$ATRA
Bullish
high confidence
Mentioned
$ATRA
alphai data visualization · based on GuruFocus
Decision brief

The 30-second read

$ATRABullishMed
01

Why it matters

The upgrade could catalyze short-term buying interest, possibly leading to a price rally.

02

Market read

The news is highly relevant for biotech investors and traders focusing on undervalued growth stocks.

03

What to watch

Market volatility, upcoming clinical trial results, and broader biotech sector trends could influence stock performance beyond analyst sentiment.

Timing: Immediate to short-term (next 1-3 months)

Background

Atara Biotherapeutics has faced market challenges, but recent analyst upgrades suggest a potential turnaround or undervaluation.

Company-level read

Ticker impact

$ATRABullishHigh confidence
Context

High relevance due to recent upgrade and significant price target change.

Expected impact

Moderate to high upward price movement in the short to medium term, contingent on market conditions and investor sentiment.

Evidence & confidence

The upgrade by a reputable analyst and the significant increase in price target, combined with the undervaluation assessment, support a bullish outlook. Nonetheless, profitability issues introduce some uncertainty.

Market effects

Sector

Potential positive impact on biotech and life sciences sectors due to increased investor interest in biotech stocks.

Regional

Limited regional impact; primarily affects US-based biotech sector.

Global

Moderate; could influence global biotech investment trends if similar upgrades occur.

Counterpoint

What could challenge this read

The profitability concerns and market struggles may outweigh the positive analyst upgrade, leading to potential downside risk.

Key entities

  • Financial Institution
    Canaccord Genuity

    A reputable investment bank that issued the upgrade.

  • Analyst
    John Newman

    Analyst at Canaccord Genuity who upgraded ATRA.

  • Company
    Atara Biotherapeutics

    Biotech company focused on cell therapies.

Read at source← All news

Related articles

AUG 12
$ATRAMed

Atara Biotherapeutics, Inc. (ATRA): Results of Operations and Financial Condition

Atara Biotherapeutics, Inc. (ATRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress Productive Type A Meeting with FDA for tabelecleucel FDA guidance provided on resubmission of tabelecleucel BLA Year over Year costs and operating expenses reduction of 87%

SEC EDGAR 8-K6 min
SEP 4
$AVAVLowAI 8/10

Jim Cramer Highlights AeroVironment’s (AVAV) Steep Competition

Jim Cramer advised against investing in AeroVironment (AVAV) despite a 40% stock drop, citing intense competition in the defense sector. The company reported record revenue of $1.98B for FY2026, up 141% YoY, driven by strong defense demand and a $464.8M U.S. Army contract. However, competition from firms like RTX and Lockheed Martin may pressure margins. Hedge fund interest grew, but short interest remains high at 9.55%.

insidermonkey.com1 min
SEP 4
$GDMedAI 9/10

General Dynamics wins $249m in US military contracts

General Dynamics (GD) won two U.S. military contracts totaling $248.9M. One is a $149.6M contract for USS Pinckney modernization, with potential value up to $149.9M. The other is a $99.3M task order for MUOS Ground Infrastructure Segment upgrades. Both contracts are sole-source and involve work through 2028, funded by fiscal 2026 budgets.

investing.com2 min
SEP 4
$LMTHighAI 9/10

Lockheed Martin wins $150 million in defense contracts

Lockheed Martin Corp received three contract modifications worth over $150 million from the U.S. Department of Defense. The largest, $90.2 million, is for the TRIDENT II Life Extension 2 program, with work spread across multiple locations. The other contracts, $40.1 million and $20.3 million, are for the MK 41 Vertical Launching System and HH-60W repairs, respectively. Completion dates range from 2027 to 2030.

investing.com2 min
SEP 4
$NVSMedAI 8/10

Novartis Pharma AG: Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Novartis announced that the Phase III Lp(a)HORIZON trial for pelacarsen did not meet its primary endpoint of reducing cardiovascular events. The study, involving 8,323 patients, showed that while pelacarsen lowered Lp(a) levels, it did not reduce cardiovascular risk. Novartis obtained rights to pelacarsen from Ionis Pharmaceuticals. Elevated Lp(a) affects about 20% of people worldwide and has no approved targeted treatment.

finanznachrichten.de2 min